Latest News

Social Factors Impact Outcomes in HCM Patients
Written by: Radcliffe Cardiology
Social Factors Impact Outcomes in HCM Patients
Clinical Frailty Scale Predicts Mortality in Heart Failure
Written by: Radcliffe Cardiology
Clinical Frailty Scale Predicts Mortality in Heart Failure
ESPRIT: Intensive BP Control Benefits Frail Patients
Written by: Radcliffe Cardiology
ESPRIT: Intensive BP Control Benefits Frail Patients
Written by: Radcliffe Cardiology
Danicamtiv Shows Promise in Genetic Dilated Cardiomyopathy
Metabolic Factors Now Key Drivers of Heart Failure
Written by: Radcliffe Cardiology
Metabolic Factors Now Key Drivers of Heart Failure
Vericiguat May Reduce Total Worsening HF Events
Written by: Radcliffe Cardiology
Vericiguat May Reduce Total Worsening HF Events
Mavacamten Reduces Biomarkers in nHCM: ODYSSEY-HCM Data
Written by: Radcliffe Cardiology
Mavacamten Reduces Biomarkers in nHCM: ODYSSEY-HCM Data
TR in HFpEF: Prognosis Varies by Mechanism
Written by: Radcliffe Cardiology
TR in HFpEF: Prognosis Varies by Mechanism
CMR Tracks ATTR-CM Progression and Treatment Response
Written by: Radcliffe Cardiology
CMR Tracks ATTR-CM Progression and Treatment Response
AVR and ATTR Therapy Improve Survival in Dual Pathology
Written by: Radcliffe Cardiology
AVR and ATTR Therapy Improve Survival in Dual Pathology

External news

Written by: Academic - advance access - HF
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial
Written by: Academic - open access - HF
Does Phenotypic Heterogeneity in Heart Failure With Preserved Ejection Fraction Imply Mechanistic Heterogeneity? The Myth of a Phenotype-Directed Therapeutic Framework and the Mandate for a Falsifiable Hypothesis
Written by: Academic - advance access - HF
Time-dependent effects of interleukin-1 blockade by anakinra in myocarditis and inflammatory cardiomyopathy
Written by: Academic - advance access - HF
Does Phenotypic Heterogeneity in Heart Failure With Preserved Ejection Fraction Imply Mechanistic Heterogeneity? The Myth of a Phenotype-Directed Therapeutic Framework and the Mandate for a Falsifiable Hypothesis
Written by: Academic - advance access - HF
Diuretic Resistance Risk and the Efficacy of Torsemide vs Furosemide: A Post-Hoc Analysis of the TRANSFORM-HF Trial
Written by: Academic - advance access - HF
What’s new in heart failure? June 2026
Written by: Academic - advance access - HF
Letter regarding the article “Independent and Dose-Dependent Contributions of Clonal Hematopoiesis and Mosaic Loss of Y to Incident Heart Failure”
Written by: Academic - advance access - HF
Circadian rhythms of core and skin temperature in heart failure
Written by: Academic - advance access - HF
Early effects of SGLT2 inhibitors in acute heart failure: an individual patient-level meta-analysis
Written by: Academic - open access - HF
Early effects of SGLT2 inhibitors in acute heart failure: an individual patient-level meta-analysis